Press Room
Congressional oversight over the 340B program
03/15/2012
A March 8, 2012 National Patient Advocate Foundation (NPAF) letter applauds Congressional efforts to better understand how the 340B program operates as it relates to the risk of improper purchases or diversion of 340B drugs, to facilitate Congressional oversight over the 340B program, and to ensure the 340B program is operating within the parameters of the law.
Increasing reactive oxygen species as a therapeutic approach to treat hereditary leiomyomatosis and renal cell carcinoma
03/15/2012
Hereditary leiomyomatosis renal cell carcinoma (HLRCC)-associated renal tumors are aggressive and tend to metastasize early. There are currently no effective forms of therapy for patients with advanced HLRCC-associated kidney cancer.
Phase I/II study of adoptive transfer of T cells in combination with zoledronic acid
03/15/2012
Human Vγ2 Vδ2-bearing T cells have recently received much attention in cancer immunotherapy. In this study, we conducted a phase I/II clinical trial of the adoptive transfer of γδ T cells to patients with advanced renal cell carcinoma.
Metabolism, Excretion, and Pharmacokinetics of Oral Brivanib in Patients with Advanced or Metastatic Solid Tumors
03/15/2012
To evaluate the pharmacokinetics, mass balance, metabolism, routes and extent of elimination, and safety of a single oral dose of [(14)C]-labeled brivanib alaninate and the safety and tolerability of brivanib after multiple doses in patients with advanced or metastatic solid tumors.
Systemic IL-12 Administration Alters Hepatic Dendritic Cell Stimulation Capabilities
03/15/2012
The liver is an immunologically unique organ containing tolerogenic dendritic cells (DC) that maintain an immunosuppressive microenvironment. Although systemic IL-12 administration can improve responses to tumors, the effects of IL-12-based treatments on DC, in particular hepatic DC, remain incompletely understood.
India uses arm-twist rule for cancer drug
03/14/2012
New Delhi, March 12: India has for the first time exercised its legal right to arm-twist pharmaceutical companies to make available expensive, patented medicines at a lower cost, allowing the generic manufacture of a cancer drug owned by a foreign company.
Kidney Cancer Association requests call to Congress
03/14/2012
We've made it easy for people to join this effort using a simple online tool, says KCA Chief Executive, Bill Bro, a 22-year kidney cancer survivor.
Outcome predictors of Gamma Knife radiosurgery for RCC
03/14/2012
To evaluate the role of stereotactic radiosurgery (SRS) in the management of brain metastases from renal cell carcinoma.
Tumor Disappearance Following Radiation
03/13/2012
The phenomenon reported by the researchers, known as the abscopal effect, occurs when localized radiation therapy delivered to a single tumor in a patient with advanced disease results in tumor disappearance outside of the irradiated area. Though the abscopal effect is extremely rare, it has been described in several cancers including melanoma, lymphoma, and kidney cancer.
Three 'targeted' cancer drugs raise fatal side effect risk
03/10/2012
Treatment with three relatively new "targeted" cancer drugs has been linked to a slightly elevated chance of fatal side effects.
News Feed| Powered by NeonCRM |